AR113454A1 - IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 - Google Patents
IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1Info
- Publication number
- AR113454A1 AR113454A1 ARP180103021A ARP180103021A AR113454A1 AR 113454 A1 AR113454 A1 AR 113454A1 AR P180103021 A ARP180103021 A AR P180103021A AR P180103021 A ARP180103021 A AR P180103021A AR 113454 A1 AR113454 A1 AR 113454A1
- Authority
- AR
- Argentina
- Prior art keywords
- agents
- inhibit
- asgr1
- compositions
- asialoglycoprotein
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente memoria da a conocer composiciones y métodos para la inhibición de la expresión génica del receptor de asialoglicoproteína 1 (ASGR1). Se dan a conocer agentes de interferencia de ARN (iARN), por ejemplo, agentes iARN de doble hebra, y conjugados agente iARN-ligando dirigido a la diana para inhibir la expresión de un gen ASGR1. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN ASGR1, opcionalmente con uno o más agentes terapéuticos adicionales. Los agentes iARN ASGR pueden utilizarse en métodos para el tratamiento de varias enfermedades y condiciones, tales como enfermedades cardiometabólicas asociadas con niveles elevados de colesterol distinto de HDL (no-HDL-C), niveles elevados de colesterol LDL (LDL-C), niveles elevados de colesterol total, y/o niveles elevados de triglicéridos (TG).The present specification discloses compositions and methods for the inhibition of asialoglycoprotein receptor 1 (ASGR1) gene expression. RNA interference agents (iRNAs) are disclosed, eg, double-stranded iRNAs, and iRNA-targeting ligand conjugates to inhibit the expression of an ASGR1 gene. Also disclosed are pharmaceutical compositions comprising one or more ASGR1 iRNA agents, optionally with one or more additional therapeutic agents. ASGR iRNA agents can be used in methods for the treatment of various diseases and conditions, such as cardiometabolic diseases associated with elevated levels of non-HDL cholesterol (non-HDL-C), elevated levels of LDL cholesterol (LDL-C), levels elevated total cholesterol, and / or elevated levels of triglycerides (TG).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762573206P | 2017-10-17 | 2017-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113454A1 true AR113454A1 (en) | 2020-05-06 |
Family
ID=70857314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103021A AR113454A1 (en) | 2017-10-17 | 2018-10-17 | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR113454A1 (en) |
-
2018
- 2018-10-17 AR ARP180103021A patent/AR113454A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
CL2020000593A1 (en) | Rnai agents and compositions to inhibit the expression of apoliprotein c-iii (apoc3). | |
ECSP20018305A (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
CL2021001195A1 (en) | Iarn agents for infection caused by the hepatitis b virus. (divisional application 201900278) | |
BR112016029041A8 (en) | use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit | |
BR112017018318A2 (en) | A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient | |
BR112017009647A2 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors to treat alzheimer's disease | |
MX346439B (en) | Methods and means to modify a plant genome. | |
BR112016029781A2 (en) | compositions and methods for inhibiting alpha-1 antitrypsin gene expression | |
BR112014032239A2 (en) | inhibitors of the micro-rnas mir-15 family | |
EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
MX2017005861A (en) | Methods to target transcriptional control at super-enhancer regions. | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
UY37936A (en) | IRAN AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF THE ASIALOGLICOPROTEIN RECEIVER 1 | |
BR112018010736A2 (en) | antisense oligonucleotides against il-34 and methods of using them | |
AR113454A1 (en) | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 | |
BR112014013374A8 (en) | Acamprosate Pills and Uses of Acamprosate | |
AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
AR113254A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
AR109293A1 (en) | IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS | |
AR113014A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
BR112014033118A8 (en) | PHARMACEUTICAL COMBINATIONS OF A CDK4/6 INHIBITOR AND A B-RAF INHIBITOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |